LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings

LENZ·Reported May 11, 2026·After market close

LENZ Therapeutics, Inc. reported Q1 2026 revenue of $1.9M, beat analyst consensus of $1.8M by $142.1K. Diluted EPS came in at $-1.32 (-149.1% YoY), missed the $-1.10 consensus by $0.22.

Revenue
$1.9Mbeat by $142.1K
Consensus: $1.8M
Diluted EPS
$-1.32missed by $0.22
Consensus: $-1.10
SEC

SEC Filings

Earnings release8-K · 0001815776-26-000035
Quarterly report10-Q · 0001815776-26-000037

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about LENZ Therapeutics, Inc.'s Q1 2026 earnings report.

LENZ Therapeutics, Inc. (LENZ) reported Q1 2026 earnings on May 11, 2026 after market close.

LENZ Therapeutics, Inc. reported revenue of $1.9M and diluted EPS of $-1.32 for Q1 2026.

Revenue beat the consensus estimate of $1.8M by $142.1K. EPS missed the consensus estimate of $-1.10 by $0.22.

Compared to the same quarter a year prior, diluted EPS declined 149.1% from $-0.53.

You can read the 8-K earnings release (0001815776-26-000035) and the 10-Q periodic report (0001815776-26-000037) directly on SEC EDGAR. The filing index links above go to sec.gov.